Abstract
The tumor-associated transmembrane carbonic anhydrase (CA, EC 4.2.1.1) isozymes IX (CA IX) and XII (CA XII) are involved in acidification of hypoxic tumors, a process correlated with poor prognosis and clinical outcome of patients harboring such tumors. This process may be reversed by inhibiting these enzymes with potent sulfonamide/sulfamate inhibitors. A series of such aromatic/heterocyclic sulfonamides incorporating 2,3,5,6-tetrafluorobenzoyl-, 2,3,5,6-tetrafluorophenylsulfonyl- and pentafluorophenylureido moieties has been investigated for its interaction with the catalytic domain of the human isozymes hCA IX and hCA XII. Some of these compounds showed excellent inhibitory properties against both isozymes IX and XII, with several subnanomolar inhibitors detected for the first time. These sulfonamides may constitute valuable candidates for the development of novel antitumor therapies based on the inhibition of such tumor-associated CA isozymes.
| Original language | English |
|---|---|
| Pages (from-to) | 211-217 |
| Number of pages | 7 |
| Journal | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Volume | 20 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 2005 |
| Externally published | Yes |
Keywords
- Antitumor drug
- Carbonic anhydrase
- Inhibitors
- Isozymes IX and XII
- Polyfluorinated derivative
- Sulfonamide
Fingerprint
Dive into the research topics of 'Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver